Exkivity

Pharma

FDA signs off on AZ spinout Dizal's lung cancer drug Zegfrovy

Dizal has gained its first FDA approval, winning an accelerated nod for Zegfrovy to become the only oral treatment for those with a rare type of NSCLC.

Kevin Dunleavy Jul 7, 2025 11:28am

Despite J&J's full nod, FDA endorses Dizal's accelerated plan

Jun 26, 2024 11:08am

Takeda takes $770M in write-downs amid Alofisel, Exkivity woes

Oct 26, 2023 12:27pm

Takeda, Kyowa Kirin, Biogen—Fierce Pharma Asia

Oct 6, 2023 8:35am

After trial flop, Takeda to pull Exkivity worldwide

Oct 3, 2023 9:55am

BMS-BeiGene, Sumitomo-Otsuka, AstraZeneca—Fierce Pharma Asia

Aug 4, 2023 8:50am